RxDoctor Payments Data

Gessica Davila

Physician Assistant · Cerritos, CANPI 1568936920

Payments from drug & device makers

$1,771in general payments, 2019–2025

Across 34 payments — averaging $52.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$611
  • Pulmonx Corporation$474
  • Actelion Pharmaceuticals US, Inc.$223
  • Sanofi$165
  • Sanofi-aventis U.S. LLC$57
  • Boehringer Ingelheim$45
  • plus $196 from 9 others

What the payments were for

  • Consulting fees$40023%
  • Food & beverage$1,31374%
  • Education$573%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,771 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$14,994
Medicare patients
104
Services billed
201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate35$435,308
OpsumitMacitentan17$198,879
Dupixent PenDupilumab35$140,279
Trelegy ElliptaFluticasone/Umeclidin/Vilanter117$78,464
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$18,658
Spiriva HandihalerTiotropium Bromide15$10,607
Spiriva RespimatTiotropium Bromide16$8,197
Albuterol Sulfate HfaAlbuterol Sulfate147$7,352
SymbicortBudesonide/Formoterol Fumarate31$7,335
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate25$5,123
Sildenafil Citrate14$4,487
BreynaBudesonide/Formoterol Fumarate24$4,367
Advair HfaFluticasone Propion/Salmeterol17$4,305
Fluticasone Propionate HfaFluticasone Propionate15$3,913
Ventolin HfaAlbuterol Sulfate23$1,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$45$443,50551 claims
Actelion Pharmaceuticals US, Inc.Opsumit$223$198,87917 claims
AstraZenecaSymbicort$14$7,33531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Cerritos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →